Drug
HCP1803-3
HCP1803-3 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
25%
Ph phase_3
2
50%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 32 (50.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_3
A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension
NCT06438172
completedphase_3
A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension
NCT05362110
completedphase_1
A Study to Evaluate the PK, Safety and Tolerability of HCP1803.
NCT05723549
completedphase_2
A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension
NCT04959305
Clinical Trials (4)
Showing 4 of 4 trials
NCT06438172Phase 3
A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension
NCT05362110Phase 3
A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension
NCT05723549Phase 1
A Study to Evaluate the PK, Safety and Tolerability of HCP1803.
NCT04959305Phase 2
A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4